SiBone (NASDAQ:SIBN) SVP Sells $655,893.15 in Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 29,665 shares of the stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $22.11, for a total value of $655,893.15. Following the sale, the senior vice president directly owned 164,444 shares in the company, valued at approximately $3,635,856.84. This trade represents a 15.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

SiBone Stock Up 5.0%

Shares of NASDAQ SIBN opened at $24.95 on Thursday. The stock has a market capitalization of $1.11 billion, a P/E ratio of -80.48 and a beta of 0.64. The stock’s fifty day moving average is $19.61 and its 200 day moving average is $16.52. SiBone has a 52 week low of $11.48 and a 52 week high of $25.92. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings data on Monday, November 2nd. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.05. The business had revenue of $55.70 million during the quarter, compared to analysts’ expectations of $55.31 million. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.62%. Sell-side analysts forecast that SiBone will post -0.40 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. TD Cowen upped their price target on shares of SiBone from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Tuesday. UBS Group lifted their price objective on shares of SiBone from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday. Needham & Company LLC decreased their price objective on shares of SiBone from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Tuesday. Weiss Ratings upgraded shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Finally, Citigroup restated a “market outperform” rating on shares of SiBone in a research report on Tuesday. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $25.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Versant Capital Management Inc lifted its holdings in shares of SiBone by 102.9% in the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock worth $29,000 after acquiring an additional 887 shares during the last quarter. D.A. Davidson & CO. grew its holdings in shares of SiBone by 2.8% during the 3rd quarter. D.A. Davidson & CO. now owns 37,814 shares of the company’s stock valued at $711,000 after purchasing an additional 1,038 shares during the last quarter. State of Wyoming grew its holdings in shares of SiBone by 70.8% during the 1st quarter. State of Wyoming now owns 10,832 shares of the company’s stock valued at $137,000 after purchasing an additional 4,490 shares during the last quarter. Quantinno Capital Management LP increased its position in SiBone by 58.2% during the 1st quarter. Quantinno Capital Management LP now owns 29,475 shares of the company’s stock worth $372,000 after purchasing an additional 10,848 shares in the last quarter. Finally, Inceptionr LLC acquired a new position in SiBone during the 1st quarter worth approximately $156,000. Institutional investors own 98.11% of the company’s stock.

More SiBone News

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Q3 results topped estimates. SiBone reported a loss of $0.08 per share, narrower than analysts’ expected $0.13 loss, and revenue of $55.7 million versus $55.3 million expected. Q3 earnings report
• Positive Sentiment: Analysts raised price targets and maintained Buy ratings. UBS lifted its target to $26 from $25, while TD Cowen raised its target to $23 from $20. These revisions indicate continued analyst support, although TD Cowen’s target is below the recent share price. UBS ratings TD Cowen ratings
• Neutral Sentiment: 2026 revenue guidance was reaffirmed. SiBone forecast full-year revenue of $231 million to $233 million, broadly in line with the $232.2 million consensus estimate, providing little change to expectations. Company Q3 results and guidance
• Negative Sentiment: Two insiders sold shares. Director Jeffrey W. Dunn sold 20,000 shares, cutting his stake by 55.47%; insider Anshul Maheshwari sold 3,738 shares. Insider selling can weigh on sentiment, though both retained shares after their transactions. Dunn SEC filing Maheshwari transaction details

SiBone Company Profile

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.